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Abstract
Early detection of liver metastases improves outcome in patients treated by chemotherapy, and is also associated with
better survival in patients treated surgically. Large liver metastases (greater than about 1–2 cm in size) should be
detectable by optimum quality CT or MRI techniques with a high level of accuracy. Microscopic metastases (smaller
than 1–2 mm in size) are rarely detected by anatomic imaging methods, but are also rarely discovered at surgery or
pathology. Alterations in perfusion caused by angiogenesis in microscopic lesions can sometimes be detected using
radionuclide or doppler perfusion techniques. Currently, attention is focused on the early and correct diagnosis of
lesions in the size range 2 mm to 2 cm. In this size range, superparamagnetic iron oxide (SPIO) enhanced MRI
is probably superior (60% sensitivity) to dual phase CT (45% sensitivity) when compared with surgery and intra-
operative ultrasound. Recent developments in CT and MRI promise some further improvement. The value of ultrasonic
contrast agents has been shown in efficacy studies, but they are yet to be assessed against state of the art CT and MRI.
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Why look for early metastatic disease?
The discovery of liver metastases is no longer an
indication for terminal care. In addition to continuing
improvements in chemotherapy, the unique regenerative
capacity of the liver parenchyma offers a basis for
resection of liver tumours which can include large and
extensive metastases. However, it is clear from surgical
studies over the last few years that the best outcome for
liver surgery is achieved when the volume of disease is
small, particularly when lesions are few in number or
solitary, and when the lesions are localised to a single
lobe. All these factors point towards early detection as a
useful contributor to improved long-term outcome. New
types of palliative and possibly curative treatments for
liver metastases, including thermal and radio-frequency
ablation, also require accurate and early detection of
tumours, and finally, the accuracy of information for
staging, stratification for treatment and prognosis is
improved by the early detection of liver disease.
When should we look for liver
metastases?
This question breaks up into two parts, both controversial.
Firstly, which primary tumours have a significant inci-
dence of liver metastases at the time of initial presentation
so that examination of the liver should be part of the
initial staging work-up? This clearly includes primary
cancers of the gastrointestinal tract, lung, advanced breast
cancer (stage 2B or above) and lymphoma; we should
probably also include melanoma and testicular tumours.
A further group of tumours shows relatively infrequent
liver metastasis, but the liver should be examined if there
is advanced local disease or lymph node metastasis at
the time of presentation—this includes renal and ovarian
tumours, also carcinomas of the prostate, bladder and
uterus, and sarcomas.
The second part of this question relates to the likelihood
of metastases developing after initial treatment of the
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primary tumour. How often should we examine the
liver and with what methods? The doubling time of
colorectal metastases has been shown from follow-up
studies to range from 60–200 days, but occasionally we
see much faster growth rates, and in other cases tumours
appear indolent over a long period of observation before
suddenly exploding into rapid growth. A reasonable
compromise is to carry out abdominal CT together with
clinical review and measurement of tumour markers at
intervals of six months over the two years following
initial treatment (e.g. in colorectal cancer). However,
the evidence for improved long-term survival of patients
undergoing surveillance, compared with those reviewed
only when symptoms recur, is not yet sufficiently
conclusive to define a standard of care.
How to look for metastases
Optimum CT technique requires thin slices and contrast
enhancement. Maximum attenuation in liver parenchyma
occurs approximately 30 seconds after the end of contrast
injection, whatever volume is used. The maximum
intensity of enhancement is greater with faster rates
of injection. Depending on the size of the patient,
100–150 ml of contrast medium of 300 mg iodine
concentration is appropriate, injected at 4–5 ml s−1.
Arterial phase acquisition should begin about 25–
30 seconds from the beginning of the injection, and portal
phase about 60–70 seconds from the start of injection.
Dual phase acquisition is worthwhile for patients with
carcinoid or pancreatic islet cell primaries, and for those
with renal or adrenal primaries. There is also a significant
minority of metastases from breast and colorectal cancer
which is hypervascular in the arterial phase and less
easily detected in the portal venous phase; whether the
additional benefit of dual phase acquisition justifies its
routine use in all patients with these pathologies remains
arguable. Patients with primary hepatocellular lesions
should also have dual phase examinations.
Optimum technique for MRI requires breath-holding
T2 acquisitions using gradient echo sequences with
superparamagnetic iron oxide (SPIO) enhancement. Pub-
lished studies have shown this technique to be more sensi-
tive than other sequences for detecting small lesions, but
the recently developed 3D breath-hold T1w sequences,
which are suitable for use with dynamic gadolinium
enhancement, may offer an equally effective alternative.
Results with ‘large’ lesions
With metastases greater than 1–2 cm in size, current
optimum CT and MR techniques should yield a very
high detection rate. In a recent study of colorectal cancer
metastases, using correlation with surgery, intra-operative
ultrasound and histology, 99% of lesions of 1 cm or
larger were detected on pre-operative MRI with SPIO
enhancement. The same patients also underwent dual
phase contrast-enhanced CT which detected 94% of
lesions in this size range. Occasional metastases will
have similar signal or attenuation characteristics to those
of the normal adjacent liver, but most of these will be
detected using contrast enhancement. Currently, SPIO-
enhanced MR appears marginally better than dual phase
CT. Multi-detector CT producing improved resolution,
and breath-hold 3D MR sequences with gadolinium both
offer possible further improvements, yet to be confirmed.
However, the lower limit of size for diagnosis by these
methods is likely to remain at about 2–3 mm.
Results with ‘small’ lesions
It is in the size range of 2 mm–2 cm that the choice and
execution of optimum imaging techniques is now critical.
With dual phase CT using single detector technology,
the typical detection rate for lesions <1 cm is 30–40%.
With SPIO-enhanced MRI, we expect to detect about
60% of lesions smaller than 1 cm, using surgery with
intra-operative ultrasound as a reference standard. The
availability of multi-detector CT with thinner slices, and
the development of 3D breath-hold T1 acquisitions with
gadolinium MRI, also using thin slices, both offer the
possibility of further improvements in the detection of
small lesions, but results from these techniques are yet
to be validated.
Microscopic metastases
All metastases start out as microscopic clumps of
tumour cells. When they grow to a size of 100–
200 microns, humoral factors stimulate the growth of
new and abnormal blood vessels around the periphery
of the lesion. At this size the lesions are not visible on
conventional imaging, but might possibly be detected
by dynamic radionuclide or ultrasound techniques as a
result of the disturbance in hepatic arterial/portal flow
ratios which is caused by the tumour angiogenesis.
Radionuclide studies in the 1980s and doppler ultrasound
studies in the 1990s both demonstrated an ability to
predict which patients with apparently normal livers at
imaging and surgery would subsequently develop overt
colorectal metastases in the liver. These techniques have
not been widely applied as other users have found their
results difficult to reproduce and clinical colleagues have
so far been reluctant to offer speculative chemotherapy on
the basis of these tests. Similar approaches are now being
tried using CT and MRI.
Conclusions and key points
Detecting metastases larger than 1–2 cm should be
achieved in 90–95% of cases with CT and 95–100% of
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cases with SPIO enhanced MRI.
Optimum CT and MRI methods are currently only
moderately successful in detecting lesions in the 2–
15 mm size-range. SPIO enhanced MRI appears superior
to CT at present, but improvements may be expected with
the use of multi-slice technology in CT, and also with
T1w 3D acquisitions in gadolinium enhanced MRI.
Detecting lesions smaller than 2 mm is rarely possible
with imaging, but might be achievable using radionuclide
or doppler based perfusion techniques.
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